Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant in Indian Women With Moderate to Severe Vasomotor Symptoms Associated With Menopause
NCT07829653Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fezolinetant in vasomotor symptoms, sponsored by Astellas Pharma. Primary endpoint: Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS) at 12 weeks. Started Oct 2026; status: recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07829653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829653.